Search Results

June 2, 2014

Ibrutinib (IMBRUVICA®) RESONATET™ Data Show Significant Improvements in Progression-Free Survival and Overall Survival in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 3 data (Abstract LBA7008) featured in the official press program of the 50th annual meeting of the American Society of Clinical Oncology and simultaneously published in The New England Journal of Medicine

Innovative Medicine

June 2, 2014

Ibrutinib (IMBRUVICA®) Three Year Follow-up of Single-Agent and Combination Study Results in Chronic Lymphocytic Leukemia

Oral presentation (Abstract 7014) and poster session (Abstract 7009) featured at the 50th annual meeting of the American Society of Clinical Oncology

Innovative Medicine

May 21, 2014

Janssen Withdraws Application In European Union Seeking Approval Of Intravenously Administered Simponi®

Innovative Medicine

May 16, 2014

OLYSIO™ (simeprevir) receives marketing authorisation in the European Union for the treatment of adults with hepatitis C genotype 1 and 4 infection

Simeprevir provides a new triple therapy treatment option, as well as the first ever 12-week interferon-free and ribavirin independent treatment regimen, in combination with sofosbuvir, for appropriate patients in Europe

Research

May 14, 2014

Janssen Labs Expanding and Accelerating Coast to Coast -- Unveils Plan to Enhance the Innovation Ecosystem with New Incubator in South San Francisco and Awards One Year of Lab Space to Three Innovative Healthcare Companies in Boston

Innovative Medicine

May 13, 2014

Supplemental New Drug Applications for Once-Monthly Long-Acting Therapy INVEGA® SUSTENNA® (paliperidone palmitate) Submitted to the U.S. FDA for the Treatment of Schizoaffective Disorder

New submission based on positive data from a 15-month schizoaffective relapse prevention study

Innovative Medicine

May 7, 2014

Janssen Submits Supplemental New Drug Application to U.S. FDA for OLYSIO™ (Simeprevir) for Once-Daily Use in Combination with Sofosbuvir for 12 Weeks for the Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C

Filing Includes Data from Treatment-Naïve Patients with Advanced Fibrosis and Null Responders with All Stages of Liver Fibrosis

Innovative Medicine

May 7, 2014

Janssen Announces Expanded Collaboration with International Partnership for Microbicides for Development and Commercialization of Dapivirine for Prevention of Sexual Transmission of HIV

Latest innovative collaboration from the Janssen Global Public Health group and significant contribution to Johnson & Johnson’s wider efforts to improve public health worldwide

Innovative Medicine

May 6, 2014

Study Found INVEGA® SUSTENNA® (paliperidone palmitate) Once-Monthly Long-Acting Therapy Delayed Time to and Reduced Risk of Relapse in Individuals with Schizoaffective Disorder as Monotherapy and Adjunctive Therapy

Demonstrated significant efficacy in manic and depressive mood symptoms and psychosis, and improved patient functioning

Innovative Medicine

May 5, 2014

Landmark Study Shows Once-Monthly Long-Acting Therapy INVEGA® SUSTENNA® (paliperidone palmitate) Significantly Delayed Time to Relapse in Patients with Schizophrenia Compared to Daily Oral Antipsychotic

First prospective, randomized clinical trial to reflect context of “real world” issues in treating schizophrenia, including recent incarceration and substance abuse

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine